Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT01727336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2. The purpose of Part 2 of this study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone in patients with advanced renal cell carcinoma (RCC).
Study identification
- NCT ID
- NCT01727336
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2012 (Actual)
- Primary completion
- Jun 2017 (Actual)
- Completion
- Nov 2017 (Actual)
- Last update posted
- Oct 6, 2022
2012 – 2017
United States locations
- U.S. sites
- 36
- U.S. states
- 22
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85718 | — |
| Highlands Oncology Group, PA | Fayetteville | Arkansas | 72758 | — |
| University of California Irvine Medical Center | Irvine | California | 92697 | — |
| University of California, Los Angeles (UCLA) - Institute of Urologic Oncology | Los Angeles | California | 90095 | — |
| Stanford Hospital and Clinics | Stanford | California | — | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | — | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | — | — |
| University of Miami | Miami | Florida | — | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | — | — |
| Loyola University Chicago | Chicago | Illinois | — | — |
| Indiana University Health Melvin & Bren Simon Cancer Center | Indianapolis | Indiana | — | — |
| Beth Israel Deaconess Med Center | Boston | Massachusetts | — | — |
| Lahey Hospital & Medical Center | Burlington | Massachusetts | — | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | — | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | — | — |
| Cancer Center Hackensack UMC | Hackensack | New Jersey | — | — |
| University of New Mexico | Albuquerque | New Mexico | — | — |
| New York Oncology Hematology, P.C. | Albany | New York | — | — |
| North Shore LIJ Center for Advance Medicine | Lake Success | New York | — | — |
| Mem Sloan Kettering Cancer Center | New York | New York | — | — |
| NYU Cancer Institute | New York | New York | — | — |
| Levin Cancer Institute | Charlotte | North Carolina | — | — |
| Cleveland Clinic | Cleveland | Ohio | — | — |
| Northwest Cancer Specialists, P.C. | Tualatin | Oregon | — | — |
| Saint Luke's University Health Network | Bethlehem | Pennsylvania | — | — |
| Penn State Milton S- Hershey Medical Center | Hershey | Pennsylvania | — | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | — | — |
| University of Pittsburgh, Hillman Cancer Center | Pittsburgh | Pennsylvania | — | — |
| Medical University of South Carolina | Charleston | South Carolina | — | — |
| Texas Oncology-South Austin | Austin | Texas | — | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | — | — |
| Texas Oncology-El Paso Cancer Treatment Center Grandview | El Paso | Texas | — | — |
| Texas Oncology - Memorial City | Houston | Texas | — | — |
| Texas Oncology - Tyler and Longview | Tyler | Texas | — | — |
| Shenandoah Oncology P.C. | Winchester | Virginia | — | — |
| University of Wisconsin, Carbone Cancer Center | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01727336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2022 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01727336 live on ClinicalTrials.gov.